BioNovelus Focuses on International Sales & Export of CR-10 Biofungicide Subject To Successful Testing & Registration

BioNovelus’ Expansion Now Includes Gunnar Light, International Sales & Distribution Management and Export Consultant


Phoenix, Dec. 21, 2016 (GLOBE NEWSWIRE) -- / BioNovelus, Inc. (PINKSHEETS: ONOV) strategically expands its position by filling the Global Distribution, Sales & Export position in addition to the two expert Agronomic Engineers. BioNovelus welcomes Gunnar Light, a global management and business development executive with over 25 years of hands-on experience working with high-technology companies ranging from startups to Fortune 20.

Light has been retained as a consultant by BioNovelus following its extensive and successful testing of Biofungicide CR-10 on coffee rust or "Roya" (Hemileia vastatrix). Light will share his expertise by focusing on strategies to expand sales, distribution and identifying export systems and channels for BioNovelus. Light has negotiated deals and managed projects in over 130 countries, working with 500 plus channel partners covering North America, Asia, Europe, Middle East, Africa, Russia, Latin America, and the Caribbean.

By focusing on global sales, distribution and export compliance for CR-10 Biofungicide, BioNovelus is seeking to promote CR-10 to becoming the standard for crop care, seeking the eradication of fungus, viruses, and bacteria related plant diseases using CR-10. Growers around the world are desperate for safe, bio-fungicide disease management of crops. With the addition of Light, management hopes to make CR-10 the worldwide “green” solution for coffee rust.

In 2007, Gunnar was appointed by the US Secretary of Commerce as a member of the Arizona District Export Council (ADEC), where he presently serves as Vice-Chair and Chair of the Export Resource Committee. His committee provides export training, mentoring and outreach to companies (SME's) interested in global business.  He is also a board member at Metro Phoenix Export Alliance (MPEXA), and the Arizona State University (ASU) Technology Entrepreneurship & Management (TEM) program. Gunnar is a frequent speaker at international seminars and conferences. Originally from Seattle, WA, he has lived, worked, studied, and traveled as an expatriate in a variety of locations in Asia, Latin America, and Europe for the last decade.

About Biofungicide CR-10
CR-10 is a proven, biodegradable, non-toxic solution that kills bacteria, fungi and spores rapidly, safely and effectively. It is a new generation of biofungicide with a unique mode of action. BioNovelus management believes that CR-10 has a broad range of uses in agricultural applications.

About BioNovelus Inc.
BioNovelus, Inc. (PINKSHEETS: ONOV) is a bioscience company that honors the environment with an innovative, cost effective and disruptive technology-based solution to agricultural and water problems.

The coffee industry is the second largest commodity market in the world to the oil industry (Source: Business Insider). Since the late 19th century, the coffee industry has been plagued by Coffee Rust or "Roya" (Hemileia vastatrix) a devastating fungus that attacks the Arabica plant. Billions of dollars and hundreds of thousands of industry jobs have been lost throughout Central America since 2012 to this Coffee Rust epidemic. (Source: ICafé). The entire coffee belt from Indonesia to Africa, to Central and South America to Vietnam and Asia is seeking a remedy to this Coffee Rust epidemic.

We are determined to help coffee growers keep the better tasting strain of the Arabica plant by fighting coffee rust through our “green” CR-10 instead of being forced to change to “hybrid” type plants. We feel very strongly that our “green”, biodegradable product is not only better for our environment but for people who enjoy the rich flavor that comes from Arabica coffee beans, whether organic or not.

BioNovelus’ primary target market is the $100Billion* plus, annual, worldwide, coffee industry. (*Source: Business Insider)

Forward-Looking Statements
This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2016 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.

There is no assurance of if and when EPA approval will be obtained for CR-10 and various applications. There is no assurance that the coffee rust application will prove commercially viable or that Mr. Light will improve our market presence and close any sales of our product internationally.  

Factors that could cause the Company’s results to differ materially from forward looking statements regarding EPA approval and the efficacy of the CR-10 results a delay in EPA approval include the lack of capital needed to complete testing, the lack of experience with pursuing approval of this product and modifications that may be demanded by the EPA of the CR-10 formula. Factors that could cause lower rates of success in CR-10 eradication of fungi in coffee plantations and marijuana fields include the method and timing of applications of CR-10, the impact of heavy rain fall the strength of fungi contamination, and other environmental conditions resulting in re-infection. Factors that may impact Mr. Light include his credibility, experience and ability to sell our products internationally.

Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, general business and economic conditions beyond the Company's control the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information, since these statements may no longer be accurate or timely.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

For additional information: http://bionovelus.com

###



            

Coordonnées